Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531411 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL3658261 | 0.88 | HSD17B10 (0.50) | SMN1; SMN2CYP3A4FFAR1FFAR4NPC1 | |
| SCHEMBL14125958 | 0.85 | HSD17B10 (0.54) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL29530799 | 0.85 | HSD17B10 (0.54) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL21339353 | 0.85 | CYP3A4 (0.61) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL3144672 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL29531114 | 0.81 | MEN1 (0.47) | CYP3A4FFAR4KMT2AALDH1A1GAA | |
| SCHEMBL6482114 | 0.81 | MEN1 (0.47) | CYP3A4FFAR4KMT2AALDH1A1GAA | |
| SCHEMBL1097812 | 0.81 | KMT2A (0.56) | SMN1; SMN2NPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL18642486 | 0.80 | DPP4 (0.46) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436004-B1 | SUBSTITUTED INDOLE COMPOUND DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-109069482-B | Substituted indole compound derivatives as inhibitors of dengue virus replication | 杨森制药公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3244886-B1 | INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3244886-B1 | INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-107428685-B | Indole derivatives as inhibitors of dengue virus replication | 杨森制药公司 | 2021-06-15 | — | — | CN | disclosed |
| CN-107001265-B | Monosubstituted or disubstituted indoles as inhibitors of dengue virus replication | 杨森制药公司 | 2021-06-15 | — | — | CN | disclosed |
| EP-3436435-B1 | SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2021-05-12 | — | — | EP | disclosed |
| EP-3436435-B1 | SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2021-05-12 | — | — | EP | disclosed |
| CN-108884033-B | Substituted indole derivatives as inhibitors of dengue virus replication | 杨森制药公司 | 2021-03-09 | — | — | CN | disclosed |
| US-10730884-B2 | Substituted indole compound derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2020-08-04 | — | — | US | disclosed |
| WO-2017167950-A1 | SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2017-10-05 | — | — | WO | disclosed |
| WO-2017167952-A1 | SUBSTITUTED INDOLE COMPOUND DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170224658-A1 | Mono- or di-substituted indoles as dengue viral replication inhibitors | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-08-10 | — | — | US | disclosed |
| US-20170224658-A1 | Mono- or di-substituted indoles as dengue viral replication inhibitors | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-08-10 | — | — | US | disclosed |
| US-20170224658-A1 | Mono- or di-substituted indoles as dengue viral replication inhibitors | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-08-10 | — | — | US | disclosed |
| EP-3201177-A1 | MONO- OR DI-SUBSTITUTED INDOLES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016113371-A1 | INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2016-07-21 | — | — | WO | disclosed |
| WO-2016113371-A1 | INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2016-07-21 | — | — | WO | disclosed |
| WO-2016050831-A1 | MONO- OR DI-SUBSTITUTED INDOLES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016050831-A1 | MONO- OR DI-SUBSTITUTED INDOLES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730884-B2 | Substituted indole compound derivatives as dengue viral replication inhibitors | IDO1, IDO2, IRF3 | SMN1; SMN2 4501/4885HDAC3 1851/4885HDAC1 2924/4885 |
| US-20170224658-A1 | Mono- or di-substituted indoles as dengue viral replication inhibitors | IDO1, IDO2, INMT | SMN1; SMN2 4607/4885HDAC3 2696/4885HDAC1 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.